Number-Needed-To-Treat (NNT) and Cost of Responses Achieved in Tyrosine Kinase Inhibitor (TKI) Treatment of Refractory Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in the United States (US)

The emergence of targeted therapies with high efficacy in small patient populations has challenged decision-makers. Ponatinib, a 3rd-generation TKI, shows activity against all common BCR-ABL single mutants including the highly resistant T315I mutant, and offers superior responses to other TKI therapy in the treatment of TKI-refractory CP-CML with or without T315I.1

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Moshe Y. Levy, Lisa McGarry, Sergio Iannazzo, Hui Huang, Silvia Chiroli Source Type: research